Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL369247 | 0.74 | CNR1 (0.30) | CNR1 | |
| SCHEMBL18527308 | 0.74 | CNR1 (0.30) | CNR1 | |
| SCHEMBL19008983 | 0.74 | CNR1 (0.33) | CNR1 | |
| SCHEMBL4559390 | 0.69 | TYR (0.36) | CNR1 | |
| SCHEMBL18300454 | 0.69 | CNR1 (0.43) | CNR1 | |
| SCHEMBL19650143 | 0.68 | — | — | |
| SCHEMBL28739 | 0.64 | LPL (0.38) | — | |
| SCHEMBL5075847 | 0.63 | PDPK1 (0.43) | CNR1 | |
| SCHEMBL1671736 | 0.62 | — | — | |
| SCHEMBL28355143 | 0.61 | IDH1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024222899-A1 | MEMBRANE-ASSOCIATED TYROSINE AND THREONINE KINASE INHIBITOR AND USE THEREOF | 海南先声再明医药股份有限公司 | 2024-10-31 | — | — | WO | disclosed |
| US-20180222884-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2018-08-09 | — | — | US | disclosed |
| US-9938255-B2 | Metalloenzyme inhibitor compounds | VPS-3, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160214959-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2016-07-28 | — | — | US | disclosed |
| US-9309273-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140349973-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-20120122780-A1 | Compounds, Compositions and Methods for Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122780-A1 | Compounds, Compositions and Methods for Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2432774-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS | Ardea Biosciences, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010135530-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-7371767-B2 | Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1893612-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20050085514-A1 | Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2005-04-21 | — | — | US | disclosed |
| EP-1458710-A4 | HETEROARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1458710-A1 | HETEROARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004030637-A2 | TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE | MERCK & CO., INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2003059904-A1 | HETEROARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122780-A1 | Compounds, Compositions and Methods for Modulating Uric Acid Levels | XDH, PON1, RBP4 | CNR1 2162/4885 |
| US-20050085514-A1 | Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRIN2C | CNR1 107/4885 |
| US-20180222884-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CNR1 4685/4885 |
| US-20140349973-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CNR1 4685/4885 |
| US-20160214959-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CNR1 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.